AmDen Pharmaceuticals Denmark ApS: Financial statements 2024
CVR: 42045403
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
AmDen Pharmaceuticals Denmark ApS (CVR 42045403) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -7,807 and a net result of DKK -7,596 compared with DKK -4,574 the year before. Equity in the 2024 report amounted to DKK 22,901. The solvency ratio was 63.6%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -7,807
- Profit/Loss
- DKK -7,596
- Equity
- DKK 22,901
- Total Assets
- DKK 36,021
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -8K | -8K | 23K | 1 |
| 2023 | - | -5K | -5K | 30K | 1 |
| 2022 | - | -7K | -15K | 35K | 1 |
| 2021 | - | 750K | 584K | 624K | 1 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
AmDen Pharmaceuticals Denmark ApS has published its annual report for 2023. Gross profit came to DKK -5,000, and the net result was DKK -4,574.
About AmDen Pharmaceuticals Denmark ApS
AmDen Pharmaceuticals Denmark ApS is a Danish company of the type Anpartsselskab based in Køge, founded in 2021. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Flemming Dyremose and Mikael Søndergaard Thomsen. The company is owned by Thomsen Pharma ApS and Flandy Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -7,514 and a net result of DKK -4,907 compared with DKK -7,596 the year before. Equity in the 2025 report amounted to DKK 17,994.